ANIXA BIOSCIENCES, INC. Equity Method Investment, Other than Temporary Impairment
ANIXA BIOSCIENCES, INC. (ANIX) reported Equity Method Investment, Other than Temporary Impairment of $127.50 thousand for the 12-month period ending 2012-10-31, per its 10-K/A filed 2014-01-17.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2014-01-17
- ANIXA BIOSCIENCES, INC. equity method investment, other than temporary impairment for fiscal 2012 was $127.50K.
| Period end | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|
| 2012-10-31 | $127.50K 10-K/A · filed 2014-01-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |